620116-46-3

Upstream product

• 620116-43-0 (S)-4-Benzyl-3-{(S)-2-[(S)-(tert-butyl-dimethyl-silanyloxy)-(6-vinyl-benzo[1,3]dioxol-5-yl)-methyl]-but-3-enoyl}-oxazolidin-2-one 
• 620116-44-1 (R)-2-[(S)-(tert-Butyl-dimethyl-silanyloxy)-(6-vinyl-benzo[1,3]dioxol-5-yl)-methyl]-but-3-en-1-ol 

Downstream Products

• 620116-48-5 (5S,6S,7R)-7-Hydroxymethyl-8-oxo-5-(3,4,5-trimethoxy-phenyl)-5,6,7,8-tetrahydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid methyl ester 
• 620622-68-6 podophyllotoxin 
• 620116-42-9 (+)-isopicropodophyllone 
• 620116-60-1 (5S,6S,7S,8S)-8-Hydroxy-7-hydroxymethyl-5-(3,4,5-trimethoxy-phenyl)-5,6,7,8-tetrahydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid methyl ester 
• 55515-07-6 (1α,2α,3α)-podophyllotoxin 
• 620116-47-4 9-(tert-butyl-dimethyl-silanyloxy)-5-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-5aH-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6-one 

Relevant academic research and scientific papers

The intramolecular carboxyarylation approach to podophyllotoxin

Since 1960, only seven plant-derived anticancer drugs have received FDA approval for commercial production. Two are semisynthetic derivatives of podophyllotoxin. This paper describes concise, highly convergent, and conceptually novel approaches to (-)-pod